Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553330 · ClinicalTrials.gov registry record · Phase 2
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT02553330 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 90 participants.
The verdict
NCT02553330, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
Interventions
- DRUG Placebo Cream
- DRUG Ruxolitinib Phosphate Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2015-11-18 |
| Est. Completion | 2017-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553330
The ClinicalTrials.gov registry entry for NCT02553330 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Cream is the first listed.
NCT02553330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553330 about?
NCT02553330 is a clinical study titled "A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)". A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
What is the current status of trial NCT02553330?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2015-11-18. Estimated completion is 2017-10-03.
What interventions are being tested in trial NCT02553330?
The interventions under investigation include: Placebo Cream (DRUG), Ruxolitinib Phosphate Cream (DRUG).
Who is sponsoring clinical trial NCT02553330?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.